Phase 2b Study of GSK4532990 in Adults With NASH (HORIZON)

May 20, 2026 updated by: GlaxoSmithKline

17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis

The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

284

Phase

Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Argentina
- - Buenos Aires, Argentina, C1061AAS
    - GSK Investigational Site
  - Capital Federal, Argentina, C1181ACH
    - GSK Investigational Site
  - Ciudad AutOnoma de Buenos Aire, Argentina, 1118
    - GSK Investigational Site
  - Ciudad Autonoma de Bueno, Argentina, C1056ABJ
    - GSK Investigational Site
  - Pilar, Argentina, B1629AHJ
    - GSK Investigational Site
  - Rosario, Argentina, 3000
    - GSK Investigational Site
  - San Miguel de Tucumán, Argentina, T4000IHE
    - GSK Investigational Site
Australia
- Western Australia
  - Nedlands, Western Australia, Australia, 6009
    - GSK Investigational Site
  - Perth, Western Australia, Australia, 6000
    - GSK Investigational Site
Belgium
- - Brussels, Belgium, 1200
    - GSK Investigational Site
  - Brussels, Belgium, 1070
    - GSK Investigational Site
  - Edegem, Belgium, 2650
    - GSK Investigational Site
Canada
- Alberta
  - Calgary, Alberta, Canada, T2N 4Z6
    - GSK Investigational Site
- Ontario
  - Toronto, Ontario, Canada, M5G 2C4
    - GSK Investigational Site
France
- - Angers, France, 49933
    - GSK Investigational Site
  - Limoges, France, 87042
    - GSK Investigational Site
  - Paris, France, 75651
    - GSK Investigational Site
  - Pierre-Bénite, France, 69310
    - GSK Investigational Site
  - Strasbourg, France, 67091
    - GSK Investigational Site
Greece
- - Athens, Greece, 11527
    - GSK Investigational Site
  - Rio Patras, Greece, 26504
    - GSK Investigational Site
  - Thessaloniki, Greece, 54642
    - GSK Investigational Site
  - Thessaloniki, Greece, 546 42
    - GSK Investigational Site
India
- - Bhubaneswar, India, 751019
    - GSK Investigational Site
  - Chandigarh, India, 160062
    - GSK Investigational Site
  - Coimbatore, India, 641005
    - GSK Investigational Site
  - Guhawati, India, 781006
    - GSK Investigational Site
  - Mumbai, India, 400012
    - GSK Investigational Site
  - Nagpur, India, 441108
    - GSK Investigational Site
  - New Delhi, India, 110070
    - GSK Investigational Site
  - Secunderabad, India, 500003
    - GSK Investigational Site
  - Surat, India, 395009
    - GSK Investigational Site
Italy
- - Florence, Italy, 50139
    - GSK Investigational Site
  - Milan, Italy, 20122
    - GSK Investigational Site
  - Modena, Italy, 41126
    - GSK Investigational Site
  - Padova, Italy, 35128
    - GSK Investigational Site
  - Palermo, Italy, 90127
    - GSK Investigational Site
  - Roma, Italy, 00168
    - GSK Investigational Site
  - Rozzano MI, Italy, 20089
    - GSK Investigational Site
  - San Giovanni Rotondo FG, Italy, 71013
    - GSK Investigational Site
Japan
- - Fukui, Japan, 918-8503
    - GSK Investigational Site
  - Fukuoka, Japan, 830-0011
    - GSK Investigational Site
  - Gifu, Japan, 500-8717
    - GSK Investigational Site
  - Gifu, Japan, 503-8502
    - GSK Investigational Site
  - Gifu, Japan, 501-6062
    - GSK Investigational Site
  - Gifu, Japan, 500-8513
    - GSK Investigational Site
  - Hiroshima, Japan, 734-8551
    - GSK Investigational Site
  - Kagawa, Japan, 761-0793
    - GSK Investigational Site
  - Kagawa, Japan, 760-8557
    - GSK Investigational Site
  - Kagawa, Japan, 760-0017
    - GSK Investigational Site
  - Kagoshima, Japan, 890-8520
    - GSK Investigational Site
  - Kanagawa, Japan, 236-0004
    - GSK Investigational Site
  - Kanagawa, Japan, 259-1143
    - GSK Investigational Site
  - Kanagawa, Japan, 216-8511
    - GSK Investigational Site
  - Nagano, Japan, 390-8621
    - GSK Investigational Site
  - Nagasaki, Japan, 856-8562
    - GSK Investigational Site
  - Nara, Japan, 634-8522
    - GSK Investigational Site
  - Numakunai, Japan, 028-3695
    - GSK Investigational Site
  - Okayama, Japan, 700-8505
    - GSK Investigational Site
  - Osaka, Japan, 564-0013
    - GSK Investigational Site
  - Saga, Japan, 849-8501
    - GSK Investigational Site
  - Shimane, Japan, 693-8501
    - GSK Investigational Site
  - Yamanashi, Japan, 409-3898
    - GSK Investigational Site
Mexico
- - Cuernavaca Morelos, Mexico, 62170
    - GSK Investigational Site
  - Guadalajara, Mexico, 44130
    - GSK Investigational Site
  - Mérida, Mexico, 97070
    - GSK Investigational Site
Panama
- - Panama City, Panama
    - GSK Investigational Site
  - Panama City, Panama, 07206
    - GSK Investigational Site
Puerto Rico
- - San Juan, Puerto Rico, 00927
    - GSK Investigational Site
South Korea
- - Incheon, South Korea, 22332
    - GSK Investigational Site
  - Seoul, South Korea, 07061
    - GSK Investigational Site
  - Seoul, South Korea, 156-755
    - GSK Investigational Site
  - Yongsan-Ku Seoul, South Korea
    - GSK Investigational Site
Spain
- - Barcelona, Spain, 08035
    - GSK Investigational Site
  - Madrid, Spain, 28041
    - GSK Investigational Site
  - Madrid, Spain, 28034
    - GSK Investigational Site
  - Madrid, Spain, 28222
    - GSK Investigational Site
  - Málaga, Spain, 29010
    - GSK Investigational Site
  - Sabadell Barcelona, Spain, 08208
    - GSK Investigational Site
  - Santander, Spain, 39008
    - GSK Investigational Site
  - Seville, Spain, 41013
    - GSK Investigational Site
  - Vigo, Spain, 36071
    - GSK Investigational Site
Turkey (Türkiye)
- - Ankara, Turkey (Türkiye), 06800
    - GSK Investigational Site
  - Kocaeli, Turkey (Türkiye), 41380
    - GSK Investigational Site
  - Rize, Turkey (Türkiye), 53200
    - GSK Investigational Site
United Kingdom
- - Cannock, United Kingdom, WS11 0BN
    - GSK Investigational Site
  - London, United Kingdom, SE5 9RS
    - GSK Investigational Site
  - Manchester, United Kingdom, M13 9NQ
    - GSK Investigational Site
  - Newcastle upon Tyne, United Kingdom, NE7 7DN
    - GSK Investigational Site
  - Nottingham, United Kingdom, NG7 2UH
    - GSK Investigational Site
United States
- Alabama
  - Homewood, Alabama, United States, 35209
    - GSK Investigational Site
- Arizona
  - Chandler, Arizona, United States, 85224
    - GSK Investigational Site
  - Chandler, Arizona, United States, 85712
    - GSK Investigational Site
  - Mesa, Arizona, United States, 85381
    - GSK Investigational Site
- Arkansas
  - Jonesboro, Arkansas, United States, 72401
    - GSK Investigational Site
  - North Little Rock, Arkansas, United States, 72117
    - GSK Investigational Site
- California
  - Huntington Park, California, United States, 90255
    - GSK Investigational Site
  - La Jolla, California, United States, 92037
    - GSK Investigational Site
  - Orange, California, United States, 92866
    - GSK Investigational Site
  - Poway, California, United States, 92064
    - GSK Investigational Site
  - Rialto, California, United States, 92377
    - GSK Investigational Site
  - Sacramento, California, United States, 95817
    - GSK Investigational Site
  - San Francisco, California, United States, 94115
    - GSK Investigational Site
  - Santa Ana, California, United States, 92704
    - GSK Investigational Site
  - Van Nuys, California, United States, 91405
    - GSK Investigational Site
- Colorado
  - Colorado Springs, Colorado, United States, 80907
    - GSK Investigational Site
- Florida
  - Bradenton, Florida, United States, 34209
    - GSK Investigational Site
  - Coral Gables, Florida, United States, 33134
    - GSK Investigational Site
  - Fort Myers, Florida, United States, 33907
    - GSK Investigational Site
  - Hallandale, Florida, United States, 33009
    - GSK Investigational Site
  - Hialeah, Florida, United States, 33016
    - GSK Investigational Site
  - Homestead, Florida, United States, 33032
    - GSK Investigational Site
  - Jupiter, Florida, United States, 33458
    - GSK Investigational Site
  - Lakewood Rch, Florida, United States, 34211
    - GSK Investigational Site
  - Miami, Florida, United States, 33126
    - GSK Investigational Site
  - Miami, Florida, United States, 33176
    - GSK Investigational Site
  - Miami, Florida, United States, 33122
    - GSK Investigational Site
  - Miami Lakes, Florida, United States, 33016
    - GSK Investigational Site
  - West Palm Beach, Florida, United States, 33401
    - GSK Investigational Site
- Georgia
  - Athens, Georgia, United States, 30607
    - GSK Investigational Site
  - Atlanta, Georgia, United States, 30328
    - GSK Investigational Site
  - Marietta, Georgia, United States, 30060
    - GSK Investigational Site
  - Snellville, Georgia, United States, 30078
    - GSK Investigational Site
- Indiana
  - Indianapolis, Indiana, United States, 46202
    - GSK Investigational Site
  - South Bend, Indiana, United States, 46635
    - GSK Investigational Site
- Iowa
  - Iowa City, Iowa, United States, 52242
    - GSK Investigational Site
- Kansas
  - Topeka, Kansas, United States, 66606
    - GSK Investigational Site
- Louisiana
  - Bastrop, Louisiana, United States, 71220
    - GSK Investigational Site
  - Marrero, Louisiana, United States, 70072
    - GSK Investigational Site
  - Metairie, Louisiana, United States, 70006
    - GSK Investigational Site
  - Monroe, Louisiana, United States, 71201
    - GSK Investigational Site
  - Shreveport, Louisiana, United States, 71105
    - GSK Investigational Site
- Maryland
  - Columbia, Maryland, United States, 21045
    - GSK Investigational Site
  - Greenbelt, Maryland, United States, 20770
    - GSK Investigational Site
- Michigan
  - Ann Arbor, Michigan, United States, 48109
    - GSK Investigational Site
  - Southfield, Michigan, United States, 48075
    - GSK Investigational Site
  - Ypsilanti, Michigan, United States, 48197
    - GSK Investigational Site
- Missouri
  - Chesterfield, Missouri, United States, 48038
    - GSK Investigational Site
- Nevada
  - Las Vegas, Nevada, United States, 89106
    - GSK Investigational Site
- New Jersey
  - Princeton, New Jersey, United States, 08648
    - GSK Investigational Site
  - Sparta, New Jersey, United States, 07871
    - GSK Investigational Site
- New York
  - New York, New York, United States, 10029
    - GSK Investigational Site
  - New York, New York, United States, 10075
    - GSK Investigational Site
  - New York, New York, United States, 10033
    - GSK Investigational Site
- North Carolina
  - Chapel Hill, North Carolina, United States, 27599
    - GSK Investigational Site
  - Durham, North Carolina, United States, 27710
    - GSK Investigational Site
  - Morehead City, North Carolina, United States, 28557
    - GSK Investigational Site
- Ohio
  - Akron, Ohio, United States, 44320
    - GSK Investigational Site
  - Springboro, Ohio, United States, 45066
    - GSK Investigational Site
  - Westlake, Ohio, United States, 44145
    - GSK Investigational Site
- Pennsylvania
  - Lancaster, Pennsylvania, United States, 17604-3200
    - GSK Investigational Site
  - Pittsburgh, Pennsylvania, United States, 15213
    - GSK Investigational Site
  - Wyomissing, Pennsylvania, United States, 19610
    - GSK Investigational Site
- Tennessee
  - Chattanooga, Tennessee, United States, 37421
    - GSK Investigational Site
  - Clarksville, Tennessee, United States, 37040
    - GSK Investigational Site
- Texas
  - Austin, Texas, United States, 78757
    - GSK Investigational Site
  - Brownsville, Texas, United States, 78520
    - GSK Investigational Site
  - Dallas, Texas, United States, 75203
    - GSK Investigational Site
  - Edinburg, Texas, United States, 78539
    - GSK Investigational Site
  - Georgetown, Texas, United States, 78626
    - GSK Investigational Site
  - Houston, Texas, United States, 77030
    - GSK Investigational Site
  - Houston, Texas, United States, 77090
    - GSK Investigational Site
  - Houston, Texas, United States, 77079
    - GSK Investigational Site
  - San Antonio, Texas, United States, 78229
    - GSK Investigational Site
  - San Antonio, Texas, United States, 78215
    - GSK Investigational Site
  - Waco, Texas, United States, 76710
    - GSK Investigational Site
- Utah
  - West Jordan, Utah, United States, 84088
    - GSK Investigational Site
- Virginia
  - Richmond, Virginia, United States, 23229
    - GSK Investigational Site
  - Richmond, Virginia, United States, 23236
    - GSK Investigational Site
- Washington
  - Seattle, Washington, United States, 98105
    - GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Description

Inclusion Criteria:

Body Mass Index (BMI) ≥25 kilogram per meter square (kg/m^2) (all ethnic origins) except for Asian participants who qualify for the study with BMI ≥23 kg/m2 at Screening.
In the opinion of the investigator, there are features of metabolic syndrome and NAFLD is the most likely cause of liver disease. Metabolic syndrome may include type 2 diabetes mellitus (T2DM), obesity, dyslipidemia and hypertension.
A liver biopsy at baseline showing NAFLD Activity Score (NAS) >=4 with at least 1 point each in steatosis, inflammation and ballooning and either Fibrosis 3 or Fibrosis 4 using NASH CRN Scoring System.
Able and willing to comply with all study assessments, including a liver biopsy at Week 52.

Exclusion Criteria:

Current alcohol consumption ≥14 standard drinks (24 units, 196 g ethanol) per week for females or ≥21 standard drinks (37 units, 294g ethanol) per week for males.
Weight reduction surgery or procedures (including gastric banding and intragastric balloon insertion) within 2 years of Screening 1 and/or planned during the study.
History of cancer within previous 2 years from Screening 1, except basal or squamous cell carcinoma of the skin or in situ cervical carcinoma or any other type of cancer which has been treated medically or surgically with curative outcome.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Quadruple

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo Placebo will be administered.
Experimental: High Dose GSK4532990	Drug: GSK4532990 GSK4532990 will be administered.
Experimental: Low Dose GSK4532990	Drug: GSK4532990 GSK4532990 will be administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Achieving ≥ 1 Stage Improvement in Histological Fibrosis with no Worsening of NASH - F3 Cohort Time Frame: At Week 52	Improvement in histological fibrosis is assessed with Clinical research network (CRN) Scoring. No worsening of NASH is defined as no increase in the NAFLD Activity Score (NAS) for steatosis, ballooning, or inflammation.	At Week 52
Percentage of Participants Achieving NASH Resolution with no Worsening of Fibrosis - F3 Cohort Time Frame: At Week 52	NASH resolution is defined as a ballooning score of 0 and an inflammation score of 0-1. No worsening of fibrosis is defined as no increase in CRN fibrosis score.	At Week 52

Secondary Outcome Measures

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Investigators

Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 2, 2023

Primary Completion (Actual)

January 31, 2026

Study Completion (Estimated)

April 5, 2027

Study Registration Dates

First Submitted

October 13, 2022

First Submitted That Met QC Criteria

October 13, 2022

First Posted (Actual)

October 17, 2022

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 20, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

218672
2022-002538-14 (EudraCT Number)
2023-507503-62-00 (Other Identifier: EU CT number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD for this study will be made available via the Clinical Study Data Request site.

IPD Sharing Time Frame

IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

IPD Sharing Access Criteria

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD Sharing Supporting Information Type

STUDY_PROTOCOL
SAP
ICF
CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-alcoholic Fatty Liver Disease

Naga P. Chalasani
DSM Nutritional Products, Inc.

Completed

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) (PUVENAFLD)

Non-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty Liver

United States
Medical College of Wisconsin
ENDRA Life Sciences, Inc.

Withdrawn

Assessment of Fatty Liver With Thermo-acoustic Device

Fatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver Disease

United States
Michael Ohliger, MD PhD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

NAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic Steatohepatitis

United States
Hywel Dda Health Board

Completed

Ultrasound and Attenuation Imaging

Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non Alcoholic Fatty Liver | Steatosis of Liver

United Kingdom
Cairo University

Recruiting

Calisthenics Versus High Intensity Interval Training in NAFL

Non-Alcoholic Fatty Liver Disease

Egypt
Nehal Abou Seada

Completed

Efficacy of Phosphatidylcholine in NAFLD

Non-Alcoholic Fatty Liver Disease
Better Therapeutics
Arizona Liver Health

Completed

Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH

Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver

United States
Badr University

Not yet recruiting

Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

Non-alcoholic Steatohepatitis NASH | Non-alcoholic Fatty Liver Disease NAFLD

Egypt
Puerta de Hierro University Hospital
Hospital Universitario Marqués de Valdecilla

Not yet recruiting

Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis (FMT-NASH)

Non-Alcoholic Fatty Liver Disease | Non Alcoholic Steatohepatitis

Spain
University Hospital, Toulouse

Not yet recruiting

Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial (S@VE-LIVER)

Non Alcoholic Fatty Liver Disease

France

Clinical Trials on Placebo

Galderma R&D

Completed

Effect of CD07805/47 Gel in Rosacea Flushing

Rosacea

Germany
SamA Pharmaceutical Co., Ltd

Unknown

Clinical Trials to Assess the Efficacy and Safety of HLIM

Acute Bronchitis | Acute Upper Respiratory Tract Infection

Korea, Republic of
National Institute on Drug Abuse (NIDA)

Completed

Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics

Cannabis Use

United States
AstraZeneca
Parexel; Spandauer Damm 130; 14050; Berlin, Germany

Completed

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Male Subjects With Type II Diabetes (T2DM)

Germany
Akeso

Not yet recruiting

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

China
Heptares Therapeutics Limited

Completed

Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects (HTL0018318)

Pharmacokinetics | Safety Issues

United Kingdom
GlaxoSmithKline

Completed

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Xuanwu Hospital, Beijing

Completed

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

Parkinson Disease

China
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
Chong Kun Dang Pharmaceutical

Unknown

Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

Hypertension | Dyslipidemias

Korea, Republic of

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Achieving ≥ 1 Stage Improvement in Histological Fibrosis with no Worsening of NASH - Pooled Cohort (F3 participants and F4 participants) Time Frame: At Week 52	Improvement in histological fibrosis is assessed with Clinical research network (CRN) Scoring. No worsening of NASH is defined as no increase in the NAFLD Activity Score (NAS) for steatosis, ballooning, or inflammation.	At Week 52
Percentage of Participants Achieving NASH Resolution with no Worsening of Fibrosis - Pooled Cohort (F3 participants and F4 participants) Time Frame: At Week 52	NASH resolution is defined as a ballooning score of 0 and an inflammation score of 0-1. No worsening of fibrosis is defined as no increase in CRN fibrosis score.	At Week 52
Change from baseline in Pro-peptide of type III collagen (Pro-C3) - F3 Cohort Time Frame: Baseline (Day 1) and at Week 24 and 52		Baseline (Day 1) and at Week 24 and 52
Change from baseline in liver fat using Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) - F3 Cohort Time Frame: Baseline (Day 1) and at Week 24 and 52		Baseline (Day 1) and at Week 24 and 52
Change from baseline in Liver stiffness measurement (LSM) by Vibration-controlled transient elastography (VCTE) - F3 Cohort Time Frame: Baseline (Day 1) and at Week 24 and 52		Baseline (Day 1) and at Week 24 and 52
Change from baseline in Enhanced Liver Fibrosis (ELF) Score - F3 Cohort Time Frame: Baseline (Day 1) and at Week 24 and 52	The ELF score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers, including tissue inhibitor of metalloproteinases-1 (TIMP-1), type III procollagen (PIIINP), and hyaluronic acid (HA). The ELF score is used as a prognostic marker for disease progression: ELF score < 9.8 : Low risk of progression, ELF score 9.8 to < 11.3 : Moderate risk of progression and ELF score > = 11.3 : High risk of progression.	Baseline (Day 1) and at Week 24 and 52
Percentage of Participants Achieving ≥30% relative reduction in liver fat from baseline using MRI-PDFF at Week 24- F3 Cohort Time Frame: At Week 24		At Week 24
Percentage of Participants Achieving ≥30% relative reduction in liver fat from baseline using MRI-PDFF at Week 52 - F3 Cohort Time Frame: At Week 52		At Week 52
Change from Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma-glutamyl transferase (GGT) (Units Per Liter) - F3 Cohort Time Frame: Baseline (Day 1) and at Week 24 and 52		Baseline (Day 1) and at Week 24 and 52
Change from baseline in Pro-peptide of type III collagen (Pro-C3) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and at Week 24 and 52		Baseline (Day 1) and at Week 24 and 52
Change from baseline in liver fat using Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and at Week 24 and 52		Baseline (Day 1) and at Week 24 and 52
Change from baseline in Liver stiffness measurement (LSM) by Vibration-controlled transient elastography (VCTE) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and at Week 24 and 52		Baseline (Day 1) and at Week 24 and 52
Change from baseline in Enhanced Liver Fibrosis (ELF) Score - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and at Week 24 and 52	The ELF score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers, including tissue inhibitor of metalloproteinases-1 (TIMP-1), type III procollagen (PIIINP), and hyaluronic acid (HA). The ELF score is used as a prognostic marker for disease progression: ELF score < 9.8 : Low risk of progression, ELF score 9.8 to < 11.3 : Moderate risk of progression and ELF score > = 11.3 : High risk of progression.	Baseline (Day 1) and at Week 24 and 52
Percentage of Participants Achieving ≥30% relative reduction in liver fat from baseline using MRI-PDFF at Week 24 - Pooled Cohort (F3 participants and F4 participants) Time Frame: At Week 24		At Week 24
Percentage of Participants Achieving ≥30% relative reduction in liver fat from baseline using MRI-PDFF at Week 52 - Pooled Cohort (F3 participants and F4 participants) Time Frame: At Week 52		At Week 52
Change from Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma-glutamyl transferase (GGT) (Units Per Liter) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and at Week 24 and 52		Baseline (Day 1) and at Week 24 and 52
Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) - F3 Cohort Time Frame: Up to Week 66		Up to Week 66
Change from Baseline in Vital Signs - Blood Pressure (millimeters of Mercury) - F3 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Temperature (Celsius) - F3 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Heart Rate (Beats per minute) - F3 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Respiratory Rate (Breaths per minute) - F3 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change From Baseline in Clinical Chemistry Parameter: total bilirubin, direct Bilirubin and creatinine (Micromoles per Liter) - F3 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) - F4 Cohort Time Frame: Up to Week 66		Up to Week 66
Change from Baseline in Vital Signs - Blood Pressure (millimeters of Mercury) - F4 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Temperature (Celsius) - F4 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Heart Rate (Beats per minute) - F4 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Respiratory Rate (Breaths per minute) - F4 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change From Baseline in Clinical Chemistry Parameter: total bilirubin, direct Bilirubin and creatinine (Micromoles per Liter) - F4 Cohort Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Up to Week 66		Up to Week 66
Change from Baseline in Vital Signs - Blood Pressure (millimeters of Mercury) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Temperature (Celsius) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Heart Rate (Beats per minute) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change from Baseline in Vital Signs - Respiratory Rate (Breaths per minute) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Change From Baseline in Clinical Chemistry Parameter: total bilirubin, direct Bilirubin and creatinine (Micromoles per Liter) - Pooled Cohort (F3 participants and F4 participants) Time Frame: Baseline (Day 1) and up to Week 52		Baseline (Day 1) and up to Week 52
Area under the concentration-time curve from time zero (pre-dose) to the last quantifiable concentration (AUC0-t) of GSK4532990 - F3 Cohort Time Frame: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose		Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose
Maximum observed concentration (Cmax) of GSK4532990- F3 Cohort Time Frame: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose		Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose
Percentage of Participants with Anti-drug Antibodies (ADA) to GSK4532990- F3 Cohort Time Frame: Up to Week 52		Up to Week 52
Area under the concentration-time curve from time zero (pre-dose) to the last quantifiable concentration (AUC0-t) of GSK4532990 - F4 Cohort Time Frame: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose		Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose
Maximum observed concentration (Cmax) of GSK4532990- F4 Cohort Time Frame: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose		Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose
Percentage of Participants with Anti-drug Antibodies (ADA) to GSK4532990- F4 Cohort Time Frame: Up to Week 52		Up to Week 52

Phase 2b Study of GSK4532990 in Adults With NASH (HORIZON)

17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Investigators

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Estimated)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Actual)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

IPD Plan Description

IPD Sharing Time Frame

IPD Sharing Access Criteria

IPD Sharing Supporting Information Type

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

Clinical Trials on Non-alcoholic Fatty Liver Disease

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations